Iterum Therapeutics plc — Director's Dealing 2018

Jun 1, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Iterum Therapeutics plc (ITRM)
CIK: 0001659323
Period of Report: 2018-05-30

Reporting Person: Chin Mark (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-05-30	Ordinary Shares	C	445576	—	Acquired	445576	Indirect
2018-05-30	Ordinary Shares	C	248721	—	Acquired	694297	Indirect
2018-05-30	Ordinary Shares	P	337606	$13.00	Acquired	1031903	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-05-30	Series B-1 Preferred Shares	$	C	445576	Disposed		Ordinary Shares (445576)	Indirect
2018-05-30	Series B-2 Preferred Shares	$	C	248721	Disposed		Ordinary Shares (248721)	Indirect

Footnotes

F1: The Series B-1 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer.

F2: The Reporting Person is an Investment Director for By Arix Bioscience Holdings Ltd.

F3: The Series B-2 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer.

F4: Not applicable.